Carboplatin

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

51 publications

Carboplatin Chemical Structure

CAS No. 41575-94-4

Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Size Price Stock Quantity  
EUR 75 In stock
EUR 105 In stock
EUR 164 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carboplatin has been cited by 51 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP6Nk0zPeLCid88US=> NHLsOmU4OiCq MlzXbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NV\DcVJPOjZzM{exNFU>
Tca8113/CBP  NGDXNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzaNk0zPeLCid88US=> MX[3NkBp M1P3cYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NGL0W2gzPjF|N{GwOS=>
Tca8113/PYM  MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\CNk0zPeLCid88US=> MYi3NkBp M3jVcIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUeyOlE{PzFyNR?=
SKOV3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS2NEBu\y:vbB?= NWftZWxpOS13IHS= MmDUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>? MmXkNlYyOzdyNEO=
SKOV3 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKwMVQh|rypL33s M{S2WVI1NzR6L{eyJIg> M2O5XYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MnPHNlYyOjV{N{O=
SKOV3 MVHBdI9xfG:|aYOgRZN{[Xl? NWLscnFJOiEQvHevcYw> MU[0PEBp M3LZZ4lv\HWlZYOgZZBweHSxc3nz NWXYVJlqOjZzMkWyO|M>
OSA M1fiVWNtd26xZ3XubYMhSXO|YYm= M4G0T|IvPS93IN88US=> NIDK[nJz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 NEXQ[|kzPjFzME[yNC=>
A549 MUjGeYN1cW:wIFHzd4F6 MYSwM|I2NzVyIN88US=> MmXONlQhcA>? Mnzj[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= M1W0RlI2QTF5M{G3
H1975 NGHycGlHfWO2aX;uJGF{e2G7 MYewM|I2NzVyIN88US=> Ml\mNlQhcA>? Moru[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= NEjzbVAzPTlzN{OxOy=>
A549 NFnMRYRHfWO2aX;uJGF{e2G7 NETVe|YxNzJ3L{WwJO69VQ>? MkHONlQhcA>? M2ryOpVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? MnS5NlU6OTd|MUe=
H1975 M{jhO2Z2[3Srb36gRZN{[Xl? M2\QWVAwOjVxNUCg{txO NVrMc5I4OjRiaB?= MUT1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> M334[|I2QTF5M{G3
A549 NWr5[VI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TnTVI2KM7:TR?= MVOyOEBp NHzq[lNqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NXXFTnhSOjV7MUezNVc>
H1975 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn0TWpuOjVizszN NHKyNlMzPCCq M2C0colvcGmkaYTzJINmdGxiZ4Lve5Rp NEO2RlUzPTlzN{OxOy=>
MDA-MB-231 M1TUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:xbnNCOC1{MkCg{txoN22u NEPRZmw4OiCq M1H5[WlEPTEEoE2gPFYh|ryP M1TxTlI2QDN5Nkmx
T47D MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMVIzOCEQvHevcYw> NWn4dZNOPzJiaB?= NWfsfGt1UUN3MNMgQUA1QC57IN88US=> MVKyOVg{PzZ7MR?=
LCTCC M1XnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD1|LklihKnDvU1? NFrNXGkzPTd5M{G2Oy=>
MCTCC NHfr[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwOPMAjeK2VQ>? MnHiNlU4PzNzNke=
MegTCC NEn4eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrTXGJKSzVyPUSuNgKBkcL3TR?= Mlm5NlU4PzNzNke=
MonoTCC MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHlT3d4UUN3ME21MlbjiIoEtV2= Mn\YNlU4PzNzNke=
MCF7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPFNlAh|ryP MWi3NkBp NHXScFdqdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>? MY[yOVc3QTB{NR?=
A-549  NG\Jd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlznNE42KM7:TR?= MViyOEBp NFTSSndFVVORwrC= M2G1dolvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= MYGyOVc2PTZ7MB?=
A-549  MXzBdI9xfG:|aYOgRZN{[Xl? NWnEWm9POC53IN88US=> NIPtPHg1QCCq MV\EUXNQyqB? M3HhdZNpd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? NVz3SlVqOjV5NUW2PVA>
A-549  MYTGeYN1cW:wIFHzd4F6 MWiwMlUh|ryP NEjXSJE1QCCq NIDHN4dFVVORwrC= Mk\6d4hwf3NiYXLldpJidnRibXnjdo91fWK3bHWg[Il{enWydHnvci=> NYDXdGlZOjV5NUW2PVA>
A-549  NFyxVlFHfWO2aX;uJGF{e2G7 NV\nU2F7OC53IN88US=> NXrqZ5JVPDhiaB?= NUHVZWl3TE2VT9Mg NXnK[IMzcW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? MWKyOVc2PTZ7MB?=
RMG-1 NGTYO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XXUmlEPTB;MkiuPEDDuSB|Lk[gcYcwVA>? NGrRZ5AzPTd{NkmxNy=>
FN-RMG-1 NE\Ne49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknPTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2= MYOyOVczPjlzMx?=
RMG-1-hFUT MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXPS4gyUUN3ME21PE4yKMLzIEKuOEBu\y:O MYiyOVczPjlzMx?=
FN-RMG-1-hFUT NVfYN|lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? M2nUeFI2PzJ4OUGz
CHP-134  MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxJO69VQ>? MYXEUXNQyqB? NXz2V4tqcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz M1e3[|I2PjV6NE[z
IMR-32 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HVdVEh|ryP NX2ycGJrTE2VT9Mg M2flUIlvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NWnLUlV{OjV4NUi0OlM>
CHP-134  MlXrSpVkfGmxbjDBd5NigQ>? Mm\0NVAh|ryPwrC= MmHUSG1UV8Li NXnUOplIcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MUKyOVY2QDR4Mx?=
IMR-32 M2\0UWZ2[3Srb36gRZN{[Xl? MWixNEDPxE4EoB?= NF[wdlRFVVORwrC= NED2OnlqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NHv4UVMzPTZ3OES2Ny=>
A549 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLZNE4zNTRyMECg{txO NV;Cd5JXPzJiaB?= NUThVlliUUN3ME2xNlYhyrFiNT6wJO69VQ>? MnPmNlU3OjV{NEO=
A549/CDDP NGDrS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmyNE4zNTRyMECg{txO M3:wdVczKGh? NVnvS5VVUUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= NWfsVYpsOjV4MkWyOFM>
H460  M2fzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXeyOEBp MorBSG1UVw>? Ml:wTWM2OD15Lkmg{txO MUOyOVU6QTl7NR?=
H460  MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV63Mlkh|ryP NXfj[4R5OjRiaB?= MnGySG1UVw>? MUDzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? NXjUb|ZCOjV3OUm5PVU>
NRK-52E NInwT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG3NuKhcMLi NEXSNFFKSzVyPUGwNEDDuSBzMj65JO69VQ>? NUPuSFJ5OjV3NkW2NFM>
RGE MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy4[GU4OsLiaNMg NX2ybGl7UUN3ME2yNkDDuSB5LkSg{txO NF:1eWEzPTV4NU[wNy=>
NRK-52E MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fBXVczyqCqwrC= NH:5cHVKSzhyPUG3PUDDuSB7LkWg{txO NXfEOZZUOjV3NkW2NFM>
RGE NGrR[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm2O|LDqGkEoB?= M3:zTGlEQDB;NkOgxtEhPy52IN88US=> MlS3NlU2PjV4MEO=
SK-OV-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS4dFU4OiCq NITYZmlKSzVyPUGwOE45KM7:TR?= Mm\WNlU2OjBzM{K=
ES-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3NkBp M{LIdmlEPTB;MUSuOkDPxE1? NX:0VINJOjV3MkCxN|I>
OVCAR-8 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS3NkBp MYPJR|UxRTl4LkCg{txO MY[yOVUzODF|Mh?=
3AO NFX5OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSN484OiCq NGOwc|RKSzVyPU[zMlQh|ryP MlTWNlU2OjBzM{K=
A2780 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXpO|IhcA>? M2DybmlEPTB;MUS1Mlch|ryP MWiyOVUzODF|Mh?=
SW626 NFm5eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzFcIxtPzJiaB?= M4nm[2lEPTB;OUeuNEDPxE1? M4flN|I2PTJyMUOy
OVCAR-3 NVXwSJBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUm3NkBp M{L6OWlEPTB;M{KuOkDPxE1? NGrkXmszPTV{MEGzNi=>
A549 M17DUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH6XIkxUUN3ME2xOVEvPTZiwsGgOVMvODZizszN MW[yOVI4PzR4MR?=
4T1 MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN M2e5ZVI2Ojd5NE[x
BALB/3T3 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H3cGlEPTB;MUSuN|AhyrFiNj62PEDPxE1? NETTdWUzPTJ5N{S2NS=>
B16 M1Hp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3XVHhIUUN3ME22OE4{OCEEsTC2MlgyKM7:TR?= M4jaUVI2Ojd5NE[x
DU 145 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>? NIDtNnkzPTJ5N{S2NS=>
FaDu NVSze|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDrbWZRUUN3ME20OU4{QSEEsTCxNU42OCEQvF2= MkHkNlUzPzd2NkG=
HCV-29T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HiUGlEPTB;NEiuOVchyrFiMkKuOFkh|ryP MmfBNlUzPzd2NkG=
HL-60 NELxd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j6cmlEPTB;MUGuNVAhyrFiND60O{DPxE1? NInzWFIzPTJ5N{S2NS=>
HT-29 M17hRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH0bFFKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= M3ezRlI2Ojd5NE[x
H146 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjNbYZKSzVyPUS5MlbDuTF|LkGg{txO M3zzZVI2OTJ2Mkiy
H187 M1r0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTuW5VKSzVyPUGyMlfDuTJwNzFOwG0> MXqyOVEzPDJ6Mh?=
H128 NELofVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\wc2lEPTB;MUC2MlTDuTlwNjFOwG0> MYWyOVEzPDJ6Mh?=
H69 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLqTWM2OD15Nj65xtEzPy56IN88US=> M4HlUVI2OTJ2Mkiy
H209 NHTP[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH0XGp5UUN3ME2yOVgvOcLzOUmuPEDPxE1? NE[4WVQzPTF{NEK4Ni=>
DMS153 NWT5NItsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXRXGpKSzVyPUW3MljDuTlwMjFOwG0> NVnQNoxoOjVzMkSyPFI>
H526 NWn1UVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTdwMtMxNU44KM7:TR?= MUCyOVEzPDJ6Mh?=
DMS114 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\nVGFKSzVyPUi1MljDuTF{Lkig{txO NIPZfo8zPTF{NEK4Ni=>
DMS53 NFnIRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj6dGs6UUN3ME2xOFYvOsLzM{[uOEDPxE1? M{XSRVI2OTJ2Mkiy
HeLa MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO1MVgxKM7:TR?= MmS1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NIrQPFAzPTFyOUO2NC=>
MCF-7 M4XRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq1MVgxKM7:TR?= NXnNWVczcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NEjpZWwzPTFyOUO2NC=>
MDA-MB-231 M3jiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\CbVUuQDBizszN MV7pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NX;sSII{OjVzMEmzOlA>
CaOV3 M3\KPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfrO|IhcA>? M2XKVmlEPTB;OE[uNUDPxE1? NEjpdJgzPTB4OEi0PS=>
OVCAR-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPUO|IhcA>? MYjJR|UxRTF5OT61JO69VQ>? NEe1cIIzPTB4OEi0PS=>
OVCAR-5 NIfSbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TYcFczKGh? NYHrTpZ1UUN3ME23OU44KM7:TR?= MkC4NlUxPjh6NEm=
SKOV-3 NWLWTYptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HWOVczKGh? M2HxUWlEPTB;NUC0JO69VQ>? NX7ZN25UOjVyNki4OFk>
OVCAR-4 MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULPR2F5PzJiaB?= NFXiUZNKSzVyPUK5NE43KM7:TR?= NUfS[FkzOjVyNki4OFk>
OVCAR-8 NYH2[3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXCRpl3PzJiaB?= Mn;1TWM2OD14OUCuNkDPxE1? NFSxN3YzPTB4OEi0PS=>
MA148 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX6NlQhcA>? M{\DTGlEPTB;OEOuOwKBkcLz4pEJNU41KM7:Zz;tcC=> NF\He3IzPDh|MUC5NS=>
A549 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3k[oRmOjRiaB?= NIe1[IhKSzVyPUe3Ok4x6oDLwsJihKkyNjlizsznM41t NGm1W4QzPDh|MUC5NS=>
MDA-MB-231 M3XZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjqeYQzPCCq NVHBU2JyUUN3ME23OFgvOOLCidMx5qCKOS5zIN88[{9udA>? NHXNbYozPDh|MUC5NS=>
NCI-ADR/RES  NV\VTot2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK5O4EzPCCq NGPzTGtKSzVyPUG3OVMvOOLCidMx5qCKPC52IN88[{9udA>? NGP4NoEzPDh|MUC5NS=>
MA148 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqOFghcA>? MlXmTWM2OD1{OD6x5qCKyrIkgJmxMlAh|rypL33s NEDCNYkzPDh|MUC5NS=>
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW0PEBp M{TzXmlEPTB;MUG4MlDjiIoEsfMAjVEvOiEQvHevcYw> NHrHRZQzPDh|MUC5NS=>
MDA-MB-231 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPBfINjPDhiaB?= NEjGOVdKSzVyPUG4N{4x6oDLwsJihKkyNjJiIN88[{9udA>? NFTUO4IzPDh|MUC5NS=>
NCI-ADR/RES  NVnjemFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jzNVQ5KGh? NUXzSol1UUN3ME2xPVMvOOLCidMx5qCKOS57IN88[{9udA>? MnvrNlQ5OzFyOUG=
MA148 M33jOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\CR|czKGh? M2C1SWlEPTB;MUOuO-KBkcLz4pEJNU4zKM7:Zz;tcC=> MXiyOFg{OTB7MR?=
A549 NVz3UphFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jiT|czKGh? NIHGT4FKSzVyPU[0MlPjiIoEsfMAjVEvOSEQvHevcYw> NVnISlNuOjR6M{GwPVE>
MDA-MB-231 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f3U|czKGh? NYTQdVJtUUN3ME25PU426oDLwsJihKkyNjFizsznM41t MlnKNlQ5OzFyOUG=
NCI-ADR/RES  NUfMSlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp M2DCZ2lEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=> MlLuNlQ5OzFyOUG=
A549 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3uO|IhcA>? NHHRcFlFVVOR MUXJR|UxRTF3Mj60NFkh|ryP M{Xkc|I1PzJzM{Kz
NCI-H157 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3NkBp MkPGSG1UVw>? MWjJR|UxRTh7Lkm3O{DPxE1? NIniXm4zPDd{MUOyNy=>
PC9 NH;Dd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Thd|czKGh? MV7HR|UxRTdzLkdCtVkvPSEEtV2= M1Xw[lI1PjF6OEC5
A549  M3\tT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV23NkBp NH7PemZISzVyPUGzOuKyOzFwNjFCuW3DqA>? NIfHZZczPDZzOEiwPS=>
PC9 MkPERZBweHSxc3nzJGF{e2G7 MX[xNFAhyrWP NUC2UXRRPzJiaB?= MX;pcoR2[2W|IHHwc5B1d3Orcx?= NFrCSYkzPDZzOEiwPS=>
A549  Mn;HRZBweHSxc3nzJGF{e2G7 NWPHc|JsOTByINM1US=> M3noUFczKGh? Mmi4bY5lfWOnczDhdI9xfG:|aYO= NX;TdlBROjR4MUi4NFk>
A549 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rodFI1KGh? NEDLO2dKSzFyPUGuOFc3KG6P M3S1VFI1Ozl4NEO3
H1299 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36xUVI1KGh? NWO0fFQ2UUNzME2wMlQ1OyCwTR?= M{LDelI1Ozl4NEO3
HCC15 NHLmc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17ac|I1KGh? MnrXTWMyOD1yLkO0OkBvVQ>? NVTEU|g3OjR|OU[0N|c>
H157 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP1U48zPCCq M4jHeWlEOTB;MD64NUBvVQ>? MnjWNlQ{QTZ2M{e=
A2780 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? M1Szb|I1OjB7Nkmz
A2780cisR M3;oeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr5TWM2OD12OD655qCKyrIkgJmzMlkh|ryP NGrY[HYzPDJyOU[5Ny=>
A2780ZD0473R NIDKVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETrZZlKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= MXeyOFIxQTZ7Mx?=
SKOV-3 NF7CcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\h[WkzUUN3ME20N{416oDLwsJihKk{NjlizszN NHvXbHYzPDJyOU[5Ny=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Synonyms JM-8, CBDCA, NSC 241240
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04493619 Not yet recruiting Drug: PLX2853|Drug: Carboplatin Gynecologic Neoplasms|Epithelial Ovarian Cancer Plexxikon August 1 2020 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID